Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Endostar with AI chemotherapy in recurrent soft tissue sarcoma
NCT04699214Phase 2Unknown
- Start
- Sep 2020
- Primary completion
- Aug 2023
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of endostar in soft tissue sarcoma (STS) (3 arms). Primary endpoint: Event-Free Survival Rate at 2 years. Status: unknown.
02
Drugs
endostar
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT04699214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04699214.